Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion TherapeuticsESPR -0.31%41 3-Year EPS without NRI Growth Rate is 68.50% as of Mar. 2026, which is 2262% above its 10-year median of 2.90. GuruFocus rates ESPR with a GF Score™ of 41/100 and a GF Value™ of $2.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 787 Drug Manufacturers companies, Esperion Therapeutics ranks better than 93.65% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 68.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Esperion Therapeutics was 68.50% per year. The lowest was -49.40% per year. And the median was 2.90% per year.
Esperion Therapeutics (NAS:ESPR) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Esperion Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ESPR vs AMPH, NIKA, BIOA: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Esperion Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 68.50% mean?
Esperion Therapeutics (ESPR) has a 3-Year EPS without NRI Growth Rate of 68.50% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Esperion Therapeutics and its competitors. This is 2262% above median its historical median of 2.90. According to the industry distribution chart, Esperion Therapeutics ranks #50 out of 787 companies in the Drug Manufacturers industry, placing it in the top 6.4%.
Is Esperion Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Esperion Therapeutics' current 3-Year EPS without NRI Growth Rate of 68.50% is 2262% above median its 10-year median of 2.90. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.70. Esperion Therapeutics' value of 68.50% is 606.2% above this industry median. Based on the distribution chart, Esperion Therapeutics ranks #50 out of 787 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' 3-Year EPS without NRI Growth Rate compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #50 out of 787 companies for 3-Year EPS without NRI Growth Rate. This places Esperion Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.70. Esperion Therapeutics' value of 68.50% is 606.2% above this benchmark. While the company's 10-year median is 2.90 vs. the industry median of 9.70, Esperion Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Esperion Therapeutics's current 3-Year EPS without NRI Growth Rate of 68.50% is 606.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Esperion Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current 3-Year EPS without NRI Growth Rate is 68.50%, which is 2262% above median its own 10-year median of 2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $3.18 — trading 39.5% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 68.50%, which is 2262% above median its 10-year median of 2.90 and 606.2% above the Drug Manufacturers industry median of 9.70. Esperion Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current 3-Year EPS without NRI Growth Rate is 68.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 39.5% above its estimated GF Value™ of $2.28.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
3-Year EPS without NRI Growth Rate: 68.50% (2262% above median its 10-year median of 2.90)
GF Value™: $2.28 vs. price of $3.18 (39.5% above fair value)
Industry Position: 606.2% above the Drug Manufacturers median (#50 of 787)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
41GF Score
Get the complete analysis for ESPR
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
